IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v30y2012i10p925-940.html
   My bibliography  Save this article

The State of Health Economic Research in South Africa

Author

Listed:
  • Paul Gavaza
  • Karen Rascati
  • Abiola Oladapo
  • Star Khoza

Abstract

Half of the articles were of poor or fair quality. Measures are needed to promote the commissioning of more and better quality health economic and pharmacoeconomic studies in South Africa. Copyright Springer International Publishing Switzerland 2012

Suggested Citation

  • Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2012. "The State of Health Economic Research in South Africa," PharmacoEconomics, Springer, vol. 30(10), pages 925-940, October.
    • Handle: RePEc:spr:pharme:v:30:y:2012:i:10:p:925-940
    DOI: 10.2165/11589450-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11589450-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/11589450-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Koch, Steven & Alaba, Olufunke, 2010. "On health insurance and household decisions: A treatment effect analysis," Social Science & Medicine, Elsevier, vol. 70(2), pages 175-182, January.
    2. Bovier, Patrick A. & Wyss, Kaspar & J. Au, Heather, 1999. "A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries," Social Science & Medicine, Elsevier, vol. 48(9), pages 1205-1220, May.
    3. Vassall, Anna & Compernolle, Phil, 2006. "Estimating the resource needs of scaling-up HIV/AIDS and tuberculosis interventions in sub-Saharan Africa: A systematic review for national policy makers and planners," Health Policy, Elsevier, vol. 79(1), pages 1-15, November.
    4. R Scott Braithwaite & Joel Tsevat, 2006. "Is Antiretroviral Therapy Cost-Effective in South Africa?," PLOS Medicine, Public Library of Science, vol. 3(1), pages 1-1, January.
    5. Clive Bell & Shantayanan Devarajan & Hans Gersbach, 2006. "The Long-Run Economic Costs of aids: A Model with an Application to South Africa," The World Bank Economic Review, World Bank, vol. 20(1), pages 55-89.
    6. Skordis, Jolene & Nattrass, Nicoli, 2002. "Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa," Journal of Health Economics, Elsevier, vol. 21(3), pages 405-421, May.
    7. B. Jönsson & G. Kobelt & J. Smolen, 2008. "The burden of rheumatoid arthritis and access to treatment: uptake of new therapies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 61-86, January.
    8. Yot Teerawattananon & Steve Russell & Miranda Mugford, 2007. "A Systematic Review of Economic Evaluation Literature in Thailand," PharmacoEconomics, Springer, vol. 25(6), pages 467-479, June.
    9. J. Lundkvist & F. Kastäng & G. Kobelt, 2008. "The burden of rheumatoid arthritis and access to treatment: health burden and costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 49-60, January.
    10. Drummond, Michael F. & Sculpher, Mark J. & Torrance, George W. & O'Brien, Bernie J. & Stoddart, Greg L., 2005. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 3, number 9780198529453.
    11. Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2010. "The State of Health Economic Evaluation Research in Nigeria," PharmacoEconomics, Springer, vol. 28(7), pages 539-553, July.
    12. Damian Walker & Julia A. Fox‐Rushby, 2000. "Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature," Health Economics, John Wiley & Sons, Ltd., vol. 9(8), pages 681-698, December.
    13. J. Lundqvist & F. Kastäng & G. Kobelt & B. Jönsson, 2008. "The burden of rheumatoid arthritis and access to treatment: determinants of access," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 87-93, January.
    14. Catherine A. Goodman & Paul G. Coleman & Anne J. Mills, 2001. "Changing the first line drug for malaria treatment—cost‐effectiveness analysis with highly uncertain inter‐temporal trade‐offs," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 731-749, December.
    15. James G Kahn & Elliot Marseille & Bertran Auvert, 2006. "Cost-Effectiveness of Male Circumcision for HIV Prevention in a South African Setting," PLOS Medicine, Public Library of Science, vol. 3(12), pages 1-10, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Gesine Meyer-Rath & Craig van Rensburg & Calvin Chiu & Rahma Leuner & Lise Jamieson & Steve Cohen, 2019. "The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case," PLOS ONE, Public Library of Science, vol. 14(2), pages 1-15, February.
    2. Susanne Mayer & Noemi Kiss & Agata Łaszewska & Judit Simon, 2017. "Costing evidence for health care decision-making in Austria: A systematic review," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-18, August.
    3. Bach Xuan Tran & Vuong Minh Nong & Rachel Marie Maher & Phuong Khanh Nguyen & Hoat Ngoc Luu, 2014. "A Systematic Review of Scope and Quality of Health Economic Evaluation Studies in Vietnam," PLOS ONE, Public Library of Science, vol. 9(8), pages 1-12, August.
    4. Kathryn Schnippel & Naomi Lince-Deroche & Theo van den Handel & Seithati Molefi & Suann Bruce & Cynthia Firnhaber, 2015. "Cost Evaluation of Reproductive and Primary Health Care Mobile Service Delivery for Women in Two Rural Districts in South Africa," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-13, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Azucena Pedraz-Marcos & Ana María Palmar-Santos & Claire Anne Hale & Juan Zarco-Colón & Milagros Ramasco-Gutiérrez & Eva García-Perea & Teresa Velasco-Ripoll & Josefina Martín-Alarcón & Nuria Sa, 2020. "Living With Rheumatoid Arthritis in Spain: A Qualitative Study of Patient Experience and the Role of Health Professionals," Clinical Nursing Research, , vol. 29(8), pages 551-560, November.
    2. Karine Chevreul & Georges Haour & Sandy Lucier & Stephanie Harvard & Marie-Laure Laroche & Xavier Mariette & Alain Saraux & Isabelle Durand-Zaleski & Francis Guillemin & Bruno Fautrel, 2014. "Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort," PLOS ONE, Public Library of Science, vol. 9(5), pages 1-9, May.
    3. Kurt Brekke & Dag Dalen & Tor Holmås, 2014. "Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 937-951, December.
    4. Evo Alemao & Maiwenn J Al & Annelies A Boonen & Matthew D Stevenson & Suzanne M M Verstappen & Kaleb Michaud & Michael E Weinblatt & Maureen P M H Rutten-van Mölken, 2018. "Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-18, October.
    5. Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi, 2014. "Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 35-43, May.
    6. Benjarin Santatiwongchai & Varit Chantarastapornchit & Thomas Wilkinson & Kittiphong Thiboonboon & Waranya Rattanavipapong & Damian G Walker & Kalipso Chalkidou & Yot Teerawattananon, 2015. "Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development," PLOS ONE, Public Library of Science, vol. 10(5), pages 1-15, May.
    7. Catherine Pitt & Catherine Goodman & Kara Hanson, 2016. "Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 9-28, February.
    8. Ulf Persson, 2012. "Value Based Pricing in Sweden: Lessons for Design?," Seminar Briefing 000141, Office of Health Economics.
    9. Benjamin Birkner & Jürgen Rech & Tom Stargardt, 2020. "Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-17, January.
    10. Márta Péntek & László Gulácsi & Bernadette Rojkovich & Valentin Brodszky & Job Exel & Werner Brouwer, 2014. "Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 83-92, May.
    11. László Gulácsi, 2010. "Future challenges for health economics and health technology assessment of biological drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 235-238, June.
    12. Bogdan Batko & Paulina Rolska-Wójcik & Magdalena Władysiuk, 2019. "Indirect Costs of Rheumatoid Arthritis Depending on Type of Treatment—A Systematic Literature Review," IJERPH, MDPI, vol. 16(16), pages 1-16, August.
    13. Jaana T Joensuu & Saara Huoponen & Kalle J Aaltonen & Yrjö T Konttinen & Dan Nordström & Marja Blom, 2015. "The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review," PLOS ONE, Public Library of Science, vol. 10(3), pages 1-27, March.
    14. Paul Gavaza & Karen Rascati & Abiola Oladapo & Star Khoza, 2010. "The State of Health Economic Evaluation Research in Nigeria," PharmacoEconomics, Springer, vol. 28(7), pages 539-553, July.
    15. Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt, 2011. "Reimbursement of pharmaceuticals: reference pricing versus health technology assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 263-271, June.
    16. Zana C Somda & Helen N Perry & Nancy R Messonnier & Mamadou H Djingarey & Salimata Ouedraogo Ki & Martin I Meltzer, 2010. "Modeling the Cost-Effectiveness of the Integrated Disease Surveillance and Response (IDSR) System: Meningitis in Burkina Faso," PLOS ONE, Public Library of Science, vol. 5(9), pages 1-10, September.
    17. Olalekan A Uthman & Taiwo Aderemi Popoola & Mubashir M B Uthman & Olatunde Aremu, 2010. "Economic Evaluations of Adult Male Circumcision for Prevention of Heterosexual Acquisition of HIV in Men in Sub-Saharan Africa: A Systematic Review," PLOS ONE, Public Library of Science, vol. 5(3), pages 1-7, March.
    18. P. Laires & F. Exposto & R. Mesquita & A. Martins & L. Cunha-Miranda & J. Fonseca, 2013. "Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 875-885, December.
    19. Oliver Fritz & Peter Mayerhofer & Reinhard Haller & Gerhard Streicher & Florian Bachner & Herwig Ostermann, 2013. "Die regionalwirtschaftlichen Effekte der österreichischen Krankenanstalten," WIFO Studies, WIFO, number 46672.
    20. Kittiphong Thiboonboon & Benjarin Santatiwongchai & Varit Chantarastapornchit & Waranya Rattanavipapong & Yot Teerawattananon, 2016. "A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 659-672, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:30:y:2012:i:10:p:925-940. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.